Abstract
In the last decades, in addition to conventional imaging techniques and magnetic resonance imaging (MRI), 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has been shown to be relevant in the detection and management of breast cancer recurrence in doubtful cases in selected groups of patients. While there are no conclusive data indicating that imaging tests, including FDG PET/CT, produce a survival benefit in asymptomatic patients, FDG PET/CT can be useful for identifying the site of relapse when traditional imaging methods are equivocal or conflicting and for identifying or confirming isolated loco-regional relapse or isolated metastatic lesions. The present narrative review deals with the potential role of FDG PET in these clinical settings by comparing its accuracy and impact with conventional imaging modalities such as CT, ultrasound, bone scan, 18F-sodium fluoride PET/CT (18F-NaF PET/CT) as well as MRI. Patient-focused perspectives in terms of patients’ satisfaction and acceptability are also discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 461-471 |
| Number of pages | 11 |
| Journal | Breast Cancer: Targets and Therapy |
| Volume | 9 |
| DOIs | |
| Publication status | Published - Jul 4 2017 |
Fingerprint
Keywords
- Breast cancer
- Positron emission tomography
- Restaging
ASJC Scopus subject areas
- Oncology
Cite this
Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence. / Piva, Roberta; Ticconi, Flavia; Ceriani, Valentina; Scalorbi, Federica; Fiz, Francesco; Capitanio, Selene; Bauckneht, Matteo; Cittadini, Giuseppe; Sambuceti, Gianmario; Morbelli, Silvia.
In: Breast Cancer: Targets and Therapy, Vol. 9, 04.07.2017, p. 461-471.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence
AU - Piva, Roberta
AU - Ticconi, Flavia
AU - Ceriani, Valentina
AU - Scalorbi, Federica
AU - Fiz, Francesco
AU - Capitanio, Selene
AU - Bauckneht, Matteo
AU - Cittadini, Giuseppe
AU - Sambuceti, Gianmario
AU - Morbelli, Silvia
PY - 2017/7/4
Y1 - 2017/7/4
N2 - In the last decades, in addition to conventional imaging techniques and magnetic resonance imaging (MRI), 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has been shown to be relevant in the detection and management of breast cancer recurrence in doubtful cases in selected groups of patients. While there are no conclusive data indicating that imaging tests, including FDG PET/CT, produce a survival benefit in asymptomatic patients, FDG PET/CT can be useful for identifying the site of relapse when traditional imaging methods are equivocal or conflicting and for identifying or confirming isolated loco-regional relapse or isolated metastatic lesions. The present narrative review deals with the potential role of FDG PET in these clinical settings by comparing its accuracy and impact with conventional imaging modalities such as CT, ultrasound, bone scan, 18F-sodium fluoride PET/CT (18F-NaF PET/CT) as well as MRI. Patient-focused perspectives in terms of patients’ satisfaction and acceptability are also discussed.
AB - In the last decades, in addition to conventional imaging techniques and magnetic resonance imaging (MRI), 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has been shown to be relevant in the detection and management of breast cancer recurrence in doubtful cases in selected groups of patients. While there are no conclusive data indicating that imaging tests, including FDG PET/CT, produce a survival benefit in asymptomatic patients, FDG PET/CT can be useful for identifying the site of relapse when traditional imaging methods are equivocal or conflicting and for identifying or confirming isolated loco-regional relapse or isolated metastatic lesions. The present narrative review deals with the potential role of FDG PET in these clinical settings by comparing its accuracy and impact with conventional imaging modalities such as CT, ultrasound, bone scan, 18F-sodium fluoride PET/CT (18F-NaF PET/CT) as well as MRI. Patient-focused perspectives in terms of patients’ satisfaction and acceptability are also discussed.
KW - Breast cancer
KW - Positron emission tomography
KW - Restaging
UR - http://www.scopus.com/inward/record.url?scp=85024096832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85024096832&partnerID=8YFLogxK
U2 - 10.2147/BCTT.S111098
DO - 10.2147/BCTT.S111098
M3 - Review article
AN - SCOPUS:85024096832
VL - 9
SP - 461
EP - 471
JO - Breast Cancer: Targets and Therapy
JF - Breast Cancer: Targets and Therapy
SN - 1179-1314
ER -